# A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

> **NCT00216541** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag B.V.** · enrollment: 110 (actual)

## Conditions studied

- Anemia
- Neoplasms

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00216541
- **Lead sponsor:** Janssen-Cilag B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216541, "A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00216541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*